NCT05410509Completed
"Embolization Before Ablation of Renal Cell Carcinoma (EMBARC)"
Source: ClinicalTrials.gov · Last updated 29 Jun 2026
Brief summary (registry, in English)
Multi-center, single arm, prospective trial to estimate safety, feasibility, technical outcomes, and clinical outcomes of percutaneous cryoablation with neo-adjuvant trans-arterial embolization of the tumor in patients with T1b renal cell carcinoma. Continuous safety monitoring will be performed with stopping rules for patient accrual or study continuation.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 25 (actual)
- First submitted
- 23 May 2022
- Start date
- 3 Jan 2024
- Primary completion date
- 19 Nov 2025
- Lead sponsor
- University of Alabama at Birmingham
- Diseases
- Kidney cancer
- NCT number
- NCT05410509
What you commit to
- Study type: Interventional
- Participants enrolled: 25
- From 3 Jan 2024 to the primary completion date, 19 Nov 2025
- 4 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Renal cell carcinoma as part of a syndrome
- Severe allergy to iodinated contrast not mitigated by steroid and diphenhydramine prophylaxis
Lab values
- Severe renal insufficiency with an Estimated Glomerular Filtration Rate (eGFR) \<30
- Uncorrectable coagulopathy, including a platelet count of \<30,000/μL and/or an international normalized ratio (INR) \>2.5 that does not respond to platelet transfusion or prothrombin complex concentrate infusion, respectively
Other
- Pregnancy
- Horseshoe kidney
- Patient unable to undergo renal mass protocol CT or MRI
- Performance status precludes enrollment as determined by the investigators
Who the study is looking for
- Aged ≥18 years
- Solid renal mass consistent with RCC on either ultrasound, MRI, or CT
- Longest tumor diameter measures 4.1-7cm
- Tumor stage T1bN0M0 without vascular invasion, adenopathy, or distant metastatic disease
- For females of reproductive potential: use of highly effective contraception for at least 1 month prior to enrollment and agreement to use such a method during study participation
- Provision of signed and dated informed consent form
- Stated willingness to comply with all study procedures and availability for the duration of the study
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (4)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Alabama at Birmingham Coordinator of this site? Confirm its status | Birmingham | United States | Unknown status |
| Thomas Jefferson Health Coordinator of this site? Confirm its status | Philadelphia | United States | Unknown status |
| Mayo Clinic Coordinator of this site? Confirm its status | Rochester | United States | Unknown status |
| Stanford Cancer Institute Coordinator of this site? Confirm its status | Stanford | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.